Navigation Links
AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
Date:4/15/2009

QUEBEC CITY, April 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it will present two posters on its PI3K inhibitor compound, AEZS-126, as well as a poster on its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, at the American Association for Cancer Research (AACR) Annual Meeting, to be held on April 18-22, 2009 at the Colorado Convention Center in Denver, Colorado.

    AEZS-126 (Poster #3705)

    - Entitled, "AEZS-126, a new orally bioavailable PI3K inhibitor with
      antitumor effects", I. Seipelt, S. Baasner, M. Gerlach, M. Teifel, J.
      Fensterle, L. Blumenstein, G. Mueller and E. Guenther, the poster
      focuses on ADMET and safety profiling of the compound, as well as in
      vivo pharmacokinetic experiments and mouse xenograft antitumor studies.

    AEZS-126 (Poster #3706)

    - Entitled, "In vitro profiling of the potent and selective PI3K
      inhibitor, AEZS-126", I. Seipelt, M. Gerlach, L. Blumenstein, G.
      Mueller, M.Teifel, E. Polymeropoulos and E. Guenther, the poster
      outlines the key in vitro characteristics of this compound that led to
      its selection for in vivo development.

    Both posters will be presented on Tuesday, April 21, 2009, between 8 a.m.
    and 12 p.m. (MT), during the Experimental and Molecular Therapeutics 23
    session in Hall B-F, Poster Section 35.

    AEZS-112 (Poster #5567)

    - Entitled, "Phase I dose-escalation, safety, and pharmacokinetic study
      of weekly oral AEZS-112, a small molecule anticancer agent in patients
      with advanced cancer and lymphoma", D. W. Northfelt, P. Griffin, H.
      Block, H. Sindermann, M. Teifel, D. Von Hoff, D. Mendelson, the poster
      outlines Phase 1 result
'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... -- Australian prostate cancer technology company Minomic International Ltd ... ,outstanding, science that uses its patented antibody. ... prostate cancer diagnostic test known as MiCheck® next year, ... the peer-reviewed Australian Museum Eureka Science Prize for ... prize is awarded for ground breaking research that has ...
(Date:9/2/2015)... Sept. 2, 2015 Veracyte, Inc. (NASDAQ: ... , president and chief executive officer, will present at ... 16, 2015 at 10:30 a.m. ET in ... live audio webcast and subsequent replay may be accessed ... be available shortly after conclusion of the presentation and ...
(Date:9/2/2015)... , September 2, 2015 BiondVax Pharmaceuticals ... the National Institute of Allergy and Infectious Diseases (NIAID), part ... Department of Health and Human Services (HHS), to launch a ... the United States in the 2015-16 timeframe. The ... candidate, Multimeric-001 (M-001), as a primer vaccine, which would be ...
(Date:9/2/2015)... Orange, California (PRWEB) , ... September 02, 2015 ... ... been a critical demand to aid high-risk surgeries. From vital sign monitoring in ... powered by Intel technology enables surgeon to make real-time clinical decisions with simultaneous ...
Breaking Biology Technology:Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3Veracyte to Present at Morgan Stanley Global Healthcare Conference 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3
... Feb. 4 With most liver cancer caused by undetected ... cases of liver cancer that are diagnosed each year could be ... gap for federal viral hepatitis education, screening, and surveillance programs, the ... the comments in conjunction with World Cancer Day 2010 , ...
... , , RICHMOND, Calif. , ... fourth quarter and full year 2009 financial results and accomplishments and provided an ... 2009 , Sangamo reported a consolidated net loss of $2.4 million , ... $2.6 million , or $0.06 per share, for the same period ...
... , , , , ... The U.S. Environmental Protection Agency,(EPA) has confirmed that ethanol made ... significantly to the reduction of greenhouse gas,(GHG) emissions. As part ... Fuel Standard (RFS2), the EPA designated,sugarcane ethanol as an advanced ...
Cached Biology Technology:NVHR: Stop Liver Cancer 'Dead in Its Tracks' By Closing Funding Gap for Viral Hepatitis Education, Screening Programs 2NVHR: Stop Liver Cancer 'Dead in Its Tracks' By Closing Funding Gap for Viral Hepatitis Education, Screening Programs 3Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 2Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 3Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 4Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 5Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 6Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 7Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 8Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 9Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 10Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 11Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 12Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 13EPA Reaffirms Sugarcane Biofuel is Advanced Renewable Fuel with 61% Less Emissions than Gasoline 2EPA Reaffirms Sugarcane Biofuel is Advanced Renewable Fuel with 61% Less Emissions than Gasoline 3EPA Reaffirms Sugarcane Biofuel is Advanced Renewable Fuel with 61% Less Emissions than Gasoline 4
(Date:8/6/2015)... , Aug. 6, 2015  Today, U.S. ... visit Crossmatch ™ to learn firsthand how ... protect data. Crossmatch is a world leader in ... and expertise are helping federal agencies and commercial ... security.   "The vast majority of ...
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics Inc. ... human interface solutions, today announced collaboration with Microsoft ... Windows 10. Microsoft leveraged Synaptics, deep expertise in ... system. Through stringent testing, Synaptics, ... certified with Microsoft,s Precision TouchPad (PTP) specification empowering ...
(Date:8/5/2015)... August 5, 2015 Transparency Market ... Recognition Market - Global Industry Analysis, Size, Share, Growth, ... for facial recognition is forecast to reach US$ 2,671.8 ... demand for surveillance systems by civil and government agencies. ... crimes and terrorist activities across the globe that would ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6
... women may worry about the effects of air pollution on ... carbon monoxide and fine particles in the air during pregnancy ... or preeclampsia -- a serious condition that arises only during ... a University at Buffalo epidemiologist. , The research was ...
... Safran, a professor at the Weizmann Institute in Israel, has ... Pierre-Gilles De Gennes Lecture Prize. The prize, accompanied by 1,000, ... (EPJE). Safran is the author of numerous articles in ... Prize, which was named after the Nobel laureate who founded ...
... cessation therapy is quickly taking shape. New evidence ... on Drug Abuse (NIDA) suggests that combining information about ... habits can accurately predict which nicotine replacement therapy will ... conceivable we,ll have a practical test that could take ...
Cached Biology News:Air pollution doesn't increase risk of preeclampsia, early delivery, study finds 2Personalized approach to smoking cessation may be reality in 3-5 years 2Personalized approach to smoking cessation may be reality in 3-5 years 3
Mouse polyclonal antibody raised against a partial recombinant CSRP3. NCBI Entrez Gene ID = 8048...
Mouse monoclonal antibody raised against a partial recombinant EOMES. NCBI Entrez Gene ID = EOMES...
...
... 2-D Sample Preparation for Membrane Proteins ... 25 membrane,protein extracts for 2-D gel analysis ... Protein Extraction Kit , (contains ... with a packed cell weight of 10 ...
Biology Products: